Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioGend Therapeutics Co's Revenue for the
three
months ended in Mar. 2026 was NT$54.9 Mil. BioGend Therapeutics Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$58.8 Mil.
Hence, BioGend Therapeutics Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.94.
BioGend Therapeutics Co (ROCO:6733) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BioGend Therapeutics Co Receivables Turnover Related Terms
BioGend Therapeutics Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BioGend Therapeutics Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co Receivables Turnover Chart
ROCO:6733 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co (ROCO:6733) has a Receivables Turnover of 0.94 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioGend Therapeutics Co and its competitors. According to the industry distribution chart, BioGend Therapeutics Co ranks #525 out of 841 companies in the Biotechnology industry, placing it in the top 62.4%.
Is BioGend Therapeutics Co's Receivables Turnover too high?
BioGend Therapeutics Co's current Receivables Turnover is 0.94. The Biotechnology industry median Receivables Turnover is 5.27. BioGend Therapeutics Co's value of 0.94 is 82.2% below this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #525 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #525 out of 841 companies for Receivables Turnover. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Receivables Turnover is 5.27. BioGend Therapeutics Co's value of 0.94 is 82.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Receivables Turnover of 0.94 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Receivables Turnover is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.71, compared to a current price of NT$27.70 — trading 53.6% below its estimated fair value. The current Receivables Turnover is 0.94 and 82.2% below the Biotechnology industry median of 5.27. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Receivables Turnover is 0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$27.70 is trading 53.6% below its estimated GF Value™ of NT$59.71.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Receivables Turnover: 0.94
GF Value™: NT$59.71 vs. price of NT$27.70 (53.6% below fair value)
Industry Position: 82.2% below the Biotechnology median (#525 of 841)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
